NJCTTQ (Nanjing CTTQ Pharma) / Abpro Corporation

Immuno-oncology (Multiple Solid Tumors)

$12.9B Global bispecific antibodies market 2024

Disease Overview

Bispecific T-cell engagers redirect cytotoxic T cells against tumor antigens by simultaneously binding CD3 on T cells and a tumor-associated antigen. The class is among the fastest-growing modalities in immuno-oncology, with applications spanning hematologic malignancies and increasingly solid tumors, where antigen selection and toxicity management remain key challenges.

Competitive Landscape

By February 2019, the bispecific T-cell engager landscape was crowded with both big-pharma and platform-biotech players. Amgen's Blincyto (blinatumomab) was the only approved T-cell engager, and Amgen's BiTE platform was the established benchmark. Competing platforms included Macrogenics' DART, Xencor's bispecific Fc, Affimed's ROCK (already partnered with Genentech), Zymeworks' Azymetric, and Regeneron's Veloci-Bi. China-based partners had become the dominant outbound dealmakers for ex-China rights to early-stage bispecifics, with NJCTTQ's parent CTTQ among the largest oncology innovators in China. The Abpro-NJCTTQ deal — $60M upfront against up to $4B in milestones — was characteristic of 2019 'biobucks' transactions: heavy back-end weighting, broad portfolio scope (multiple undisclosed targets), and Greater China rights structure. FierceBiotech ranked the deal #4 among the top 15 biopharma licensing deals of 2019, but cautioned it was 'remarkable not only for its value but because the cash comes from China,' reflecting analyst skepticism about realization of milestone payments. Abpro had postponed an $86M IPO in 2018 and used the NJCTTQ deal as a non-dilutive funding source to advance its bispecific pipeline.